Sepsis & antibiotic Target hospitals and large clinics with high sepsis caseloads to shorten time to effective therapy using Accelerate Pheno system, which reports phenotypic antibiotic susceptibility in about 7 hours from positive blood cultures.

Time to action Position as a time-saving solution that accelerates antimicrobial stewardship programs by enabling clinicians to optimize antibiotic selection days earlier, potentially improving patient outcomes and reducing length of stay.

Mid-market focus Sales strategy should emphasize medium-sized hospitals and healthcare networks given the company’s staffing and revenue range, aligning with buyers seeking scalable, automated diagnostics without large enterprise-level deployment.

Clinical differentiation Highlight the automation of sample prep and rapid phenotypic results as a differentiator from competitors, reinforcing how faster actionable data supports better clinical decisions and potential market share gains.

Favorable funding posture Leverage modest revenue and recent funding to pursue case studies and early-adopter deployments, offering ROI analysis to potential customers through pilot programs and threshold-based pricing discussions.